Royalty Pharma PLC reports results for the quarter ended in March - Earnings Summary

Royalty Pharma

09/05/2023 14:33

* Royalty Pharma PLC  RPRX.OQ  reported quarterly adjusted
earnings of $1.60​​ per share for the quarter ended in March.
The mean expectation of six analysts for the quarter was
for earnings of $1.27 per share.
    * Revenue rose 21.7% to $684.00 million from a year ago;
analysts
expected $852.90 million. 
    * Royalty Pharma PLC's reported EPS for the quarter was 56
cents​.
    * The mean earnings estimate of analysts had risen by
about 58.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Royalty Pharma PLC shares had fallen by 1.4% this
quarter and
lost 10.1% so far this year.
    * The company reported quarterly net income of $341 million.
    * Wall Street's median 12-month price target for Royalty
Pharma
PLC is $51.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      1.27           1.60           Beat
 Dec. 31 2022      1.47           1.56           Beat
 Sep. 30 2022      0.72           0.72           Met
 Jun. 30 2022      0.78           0.79           Beat